$SUVEN

SUVEN LIFE SCIENCES : POSITIVE PHASE-3 UPDATE FOR ALZHEIMER'S DRUG 🧠💊 • ✅ Independent DSMB completed safety review and interim analysis of Masupirdine (SUVN-502) Phase-3 study • 👍 DSMB recommended the trial continue without any changes • 🚫 No safety concerns identified; no protocol modifications required • 📊 Interim analysis at ~50% study completion confirmed no increase in sample size needed • 👥 Over 88% of planned patients enrolled so far • 📅 Enrollment expected to be completed by September 2026 • 🧪 Top-line results expected in Q2 CY2027 • 🚀 Management indicated strong enrollment momentum, with potential to advance timelines further 🟢 Impact: Positive (Major clinical milestone with clean safety profile, reducing development risk and improving confidence in Masupirdine's prospects.)